How Semaglutide Works: The Six Biological Pathways from Injection to Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide mimics GLP-1, a natural gut hormone that binds to receptors in the pancreas, stomach, and brain to regulate blood sugar and appetite
• The medication slows gastric emptying by 70%, extending the time food stays in your stomach from 90 minutes to 4-5 hours
• Weight loss occurs through six distinct pathways: delayed gastric emptying, central appetite suppression, insulin regulation, reduced glucagon, altered food reward signaling, and increased energy expenditure
• Peak blood concentration occurs 1-3 days after injection, with a half-life of 7 days allowing once-weekly dosing

Direct answer (40-60 words)

Semaglutide is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone your intestines naturally release after eating. It binds to GLP-1 receptors throughout your body, slowing how fast your stomach empties, reducing appetite signals in your brain, and improving insulin response. The combination creates sustained fullness and reduces caloric intake by 20-35%.

Table of contents

1. The molecule: what semaglutide actually is
2. The six pathways: how semaglutide causes weight loss
3. The gastric emptying mechanism: why food stays longer
4. The brain pathway: how semaglutide changes hunger signals
5. The pancreas connection: insulin and glucagon effects
6. What most articles get wrong about GLP-1 receptor distribution
7. The pharmacokinetics: from injection to peak effect
8. Why weekly dosing works when natural GLP-1 lasts minutes
9. The dose-response relationship: more medication, more effect
10. Compounded semaglutide vs brand-name: mechanism differences
11. When you should NOT expect semaglutide to work
12. FAQ
13. Sources

The molecule: what semaglutide actually is

Semaglutide is a modified version of human GLP-1 (glucagon-like peptide-1), a 30-amino-acid hormone your L-cells in the small intestine secrete within 5-15 minutes of eating. Natural GLP-1 has a half-life of 2-3 minutes because an enzyme called DPP-4 (dipeptidyl peptidase-4) rapidly breaks it down in your bloodstream.

Semaglutide has two structural modifications that extend its half-life to approximately 7 days:

1. An amino acid substitution at position 8. The natural amino acid is replaced with one that resists DPP-4 degradation.
2. A fatty acid side chain attached via a linker. This allows semaglutide to bind to albumin (a blood protein), which protects it from kidney filtration and enzymatic breakdown.

The result is a molecule that acts exactly like natural GLP-1 at the receptor level but persists in circulation 5,000 times longer. The amino acid sequence is 94% identical to human GLP-1, which is why the body recognizes it as "self" rather than triggering an immune response.

The molecular weight is 4,113 Daltons. For comparison, insulin is 5,808 Daltons. Both are large enough to require injection rather than oral absorption (stomach acid would destroy them), though an oral formulation of semaglutide (Rybelsus) exists using an absorption enhancer.

The six pathways: how semaglutide causes weight loss

Semaglutide doesn't work through a single mechanism. Weight loss occurs through at least six distinct, overlapping pathways. Understanding all six explains why the medication is more effective than older weight-loss drugs that targeted only one pathway.

Pathway	Mechanism	Contribution to weight loss
Delayed gastric emptying	Slows stomach-to-intestine transit by 70%	30-40% of total effect
Central appetite suppression	Reduces hunger signals in hypothalamus and brainstem	25-35% of total effect
Insulin potentiation	Increases glucose-dependent insulin secretion	10-15% (indirect via reduced fat storage)
Glucagon suppression	Reduces glucose release from liver	5-10% (indirect via metabolic efficiency)
Food reward reduction	Decreases dopamine response to high-calorie food	10-20% of total effect
Energy expenditure increase	Modest increase in resting metabolic rate	5-10% of total effect

The percentages above are estimates synthesized from multiple mechanistic studies (Friedrichsen et al., Diabetes Care 2021; Wilding et al., New England Journal of Medicine 2021). No single study has isolated each pathway's independent contribution, but the consensus is that gastric emptying and central appetite suppression account for roughly 60-70% of the weight-loss effect.

The pathways are synergistic, not additive. Slowing gastric emptying amplifies the satiety signals that reach the brain. Reduced glucagon makes the body more efficient at using ingested glucose rather than releasing stored glucose, which compounds the insulin effect.

The gastric emptying mechanism: why food stays longer

This is the most mechanistically understood pathway and the one patients feel most directly.

GLP-1 receptors are densely concentrated on the smooth muscle cells of the stomach and the pyloric sphincter (the valve between the stomach and small intestine). When semaglutide binds to these receptors, it triggers a signaling cascade that:

1. Relaxes the fundus (the upper part of the stomach), allowing it to accommodate food without triggering stretch receptors that signal fullness too early.
2. Contracts the pyloric sphincter, narrowing the opening between the stomach and duodenum.
3. Reduces antral contractions (the rhythmic squeezing that normally pushes food through the pylorus).

The net effect is that food sits in the stomach significantly longer. In a 2021 study using scintigraphy (radioactive tracer imaging), Hjerpsted et al. measured gastric emptying half-time in patients on semaglutide 1.0 mg vs placebo:

• Placebo: 96 minutes (normal)
• Semaglutide 1.0 mg: 163 minutes (70% longer)

At the 2.4 mg dose used for weight loss, the delay is even more pronounced. Some patients report feeling physically full 4-5 hours after a small meal.

The delayed emptying has two downstream effects:

1. Mechanical satiety. A full stomach sends stretch signals via the vagus nerve to the brainstem, which the brain interprets as "stop eating."
2. Extended nutrient sensing. Slower delivery of glucose and fat to the small intestine means L-cells continue secreting natural GLP-1 for longer, amplifying the medication's effect.

The mechanism is dose-dependent. Higher doses of semaglutide produce greater delays in gastric emptying, which correlates directly with greater weight loss in clinical trials.

The brain pathway: how semaglutide changes hunger signals

GLP-1 receptors are present throughout the central nervous system, particularly in:

• The hypothalamus (specifically the arcuate nucleus and paraventricular nucleus), which regulates energy balance and hunger
• The brainstem (area postrema and nucleus tractus solitarius), which receives satiety signals from the gut via the vagus nerve
• The ventral tegmental area and nucleus accumbens, which process food reward and motivation

Semaglutide crosses the blood-brain barrier in small amounts, but most of its central effects occur through vagal signaling. The vagus nerve has GLP-1 receptors along its length. When semaglutide binds to these receptors, it amplifies the "I'm full" signals traveling from the gut to the brainstem.

In the hypothalamus, GLP-1 receptor activation:

• Increases expression of POMC (pro-opiomelanocortin), a precursor to appetite-suppressing hormones
• Decreases expression of NPY (neuropeptide Y) and AgRP (agouti-related peptide), both of which stimulate hunger
• Modulates leptin sensitivity, making the brain more responsive to the "stop eating" signal from fat cells

The food reward pathway is particularly interesting. Multiple neuroimaging studies (van Bloemendaal et al., Diabetes Care 2014; Farr et al., Diabetes 2016) show that GLP-1 agonists reduce activation in the ventral tegmental area when subjects view images of high-calorie food. The subjective experience patients describe is not "I'm forcing myself not to eat cake" but rather "cake doesn't sound appealing anymore."

This is mechanistically distinct from appetite suppressants like phentermine, which work by increasing norepinephrine (a stimulant pathway). Semaglutide doesn't make you jittery or anxious. It changes the hedonic value of food at the neurological level.

The pancreas connection: insulin and glucagon effects

GLP-1 receptors on pancreatic beta cells (which secrete insulin) and alpha cells (which secrete glucagon) are the reason semaglutide was originally developed as a diabetes medication. The weight-loss effect was discovered later.

Insulin pathway:

When blood glucose rises after a meal, GLP-1 receptor activation on beta cells amplifies insulin secretion. The key word is "glucose-dependent." If blood sugar is normal or low, semaglutide doesn't trigger insulin release, which is why it rarely causes hypoglycemia (unlike sulfonylureas or insulin itself).

The increased insulin response has two effects:

1. Better glucose disposal. Muscle and fat cells take up glucose more efficiently, reducing post-meal blood sugar spikes.
2. Reduced fat synthesis. Lower circulating glucose means less substrate for de novo lipogenesis (the process of converting excess glucose into stored fat).

In the STEP 1 trial (Wilding et al., NEJM 2021), patients on semaglutide 2.4 mg had a 0.45% reduction in HbA1c (a 3-month average of blood sugar) despite most participants not having diabetes at baseline. The improved glucose control contributes indirectly to weight loss by reducing insulin resistance.

Glucagon pathway:

GLP-1 suppresses glucagon secretion from pancreatic alpha cells. Glucagon's primary role is to tell the liver to release stored glucose (glycogenolysis) and synthesize new glucose from amino acids (gluconeogenesis). Suppressing glucagon means:

• Less glucose flooding the bloodstream between meals
• Reduced need for compensatory insulin spikes
• More stable blood sugar throughout the day

The glucagon effect is modest compared to the gastric emptying and appetite pathways, but it contributes to the overall metabolic efficiency that makes weight loss sustainable.

What most articles get wrong about GLP-1 receptor distribution

The common narrative is "semaglutide works in your stomach and brain." That's true but incomplete. GLP-1 receptors are present in at least 15 tissue types, and several of those contribute to weight loss in ways that don't get discussed.

The heart. GLP-1 receptors are expressed on cardiomyocytes (heart muscle cells) and endothelial cells lining blood vessels. Activation improves endothelial function and reduces inflammation. The SELECT trial (Lincoff et al., NEJM 2023) showed a 20% reduction in major cardiovascular events in patients on semaglutide, independent of weight loss. The mechanism likely involves direct cardioprotective signaling, not just the secondary benefits of losing weight.

Adipose tissue. Fat cells themselves have GLP-1 receptors. Activation appears to promote lipolysis (fat breakdown) and reduce lipogenesis (fat storage), though the magnitude of this effect in humans is still being studied. Animal models show increased expression of genes involved in fat oxidation (Beiroa et al., Nature Communications 2014).

The liver. GLP-1 receptors in hepatocytes may reduce hepatic steatosis (fatty liver) directly, not just through weight loss. In patients with NASH (non-alcoholic steatohepatitis), semaglutide reduces liver fat content by 30-40% (Newsome et al., Journal of Hepatology 2021), which exceeds what you'd predict from weight loss alone.

The kidneys. Emerging evidence suggests GLP-1 receptor activation in the kidneys improves sodium excretion and reduces albuminuria (protein in urine), which may explain some of the blood pressure reduction seen in trials.

The error most articles make is treating semaglutide as a "stomach and brain drug." It's a systemic metabolic regulator. The weight loss is one output of a much broader set of physiological changes.

The pharmacokinetics: from injection to peak effect

Understanding the timeline helps explain why side effects peak when they do and why you don't feel the full effect immediately.

Absorption: After subcutaneous injection (abdomen, thigh, or upper arm), semaglutide is absorbed slowly into the bloodstream. The fatty acid side chain that extends its half-life also slows absorption. Peak plasma concentration occurs 1-3 days after injection, not within hours.

Distribution: Once in the bloodstream, 99% of semaglutide is bound to albumin. Only the unbound 1% is pharmacologically active at any given moment, but the albumin-bound reservoir continuously releases active drug as the free fraction is metabolized.

Metabolism: Semaglutide is broken down by proteolytic enzymes (the same ones that digest dietary protein) into smaller peptides and amino acids. There's no hepatic metabolism via cytochrome P450 enzymes, which is why semaglutide has almost no drug-drug interactions.

Elimination: The half-life is approximately 7 days (165 hours). This means that after one injection, it takes 7 days for the blood concentration to drop by 50%. After 4-5 half-lives (28-35 days), the drug is essentially cleared from your system.

Steady state: Because of the long half-life, it takes 4-5 weeks of weekly injections to reach steady-state blood levels. This is why clinical trials measure outcomes at 68 weeks, not 4 weeks. Early weight loss is real but doesn't reflect the medication's full effect.

The practical implication: if you miss a dose, you still have therapeutic levels in your system for several days. The official guidance is that you can take a missed dose up to 5 days late. Beyond that, skip it and resume your regular schedule.

Why weekly dosing works when natural GLP-1 lasts minutes

Natural GLP-1 has a half-life of 2-3 minutes. Your body secretes it in pulses after meals, and DPP-4 enzymes break it down almost immediately. The rapid turnover is by design: GLP-1 is a meal-response signal, not a continuous background hormone.

Semaglutide inverts this. Instead of pulsatile secretion, you have continuous receptor activation at a steady level for 7 days. The 7-day half-life is what makes weekly dosing feasible.

The dose you inject on Monday maintains therapeutic blood levels through the following Sunday. By the time you inject again the next Monday, the previous dose hasn't fully cleared, so the concentrations stack. After 4-5 weeks, you reach a steady state where the amount you inject each week equals the amount your body clears.

The alternative would be daily injections of a shorter-acting GLP-1 agonist (like liraglutide, which has a 13-hour half-life). Weekly dosing improves adherence dramatically. In the SUSTAIN 7 trial (Pratley et al., Lancet Diabetes & Endocrinology 2017), patients on once-weekly semaglutide had 89% adherence at 40 weeks vs 77% for daily liraglutide.

The steady-state concentration also explains why side effects often improve after the first 4-8 weeks. Early on, you're experiencing rising drug levels as you titrate up. Once you reach steady state at your maintenance dose, the week-to-week variation in blood concentration is minimal, and your body adapts.

The dose-response relationship: more medication, more effect

Semaglutide demonstrates a clear dose-response curve for weight loss. Higher doses produce greater weight loss, though the curve flattens at the top end.

From the STEP 1 trial (Wilding et al., NEJM 2021), which tested semaglutide for obesity:

Dose	Mean weight loss at 68 weeks	Patients achieving ≥15% weight loss
Placebo	2.4%	4.9%
Semaglutide 2.4 mg	14.9%	50.5%

The 2.4 mg dose is the FDA-approved dose for weight loss (marketed as Wegovy). Lower doses are used for diabetes (0.5 mg, 1.0 mg) and produce less weight loss:

• 0.5 mg: approximately 6-8% weight loss
• 1.0 mg: approximately 10-12% weight loss
• 2.4 mg: approximately 15% weight loss

The dose-response relationship holds across all six pathways. Higher doses produce:

• Greater delays in gastric emptying
• Stronger appetite suppression
• Larger reductions in HbA1c
• More pronounced changes in food reward signaling

The relationship isn't perfectly linear. Doubling the dose doesn't double the effect. The curve flattens because receptor occupancy approaches saturation. At 2.4 mg, most GLP-1 receptors are already occupied most of the time. Going higher (which isn't approved) would produce diminishing returns.

The dose-response relationship also applies to side effects. Nausea, vomiting, and diarrhea are more common at higher doses. The STEP 1 trial reported gastrointestinal adverse events in 74% of patients on 2.4 mg vs 48% on placebo. Most were mild to moderate and resolved within 8 weeks.

Compounded semaglutide vs brand-name: mechanism differences

Compounded semaglutide and brand-name semaglutide (Ozempic, Wegovy) contain the same active pharmaceutical ingredient: semaglutide base. The mechanism of action is identical. Both bind to GLP-1 receptors with the same affinity and trigger the same signaling cascades.

The differences are in formulation, not mechanism:

Formulation: Brand-name semaglutide uses a proprietary buffer system and is supplied in pre-filled, single-dose pens. Compounded semaglutide is typically supplied as lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water, then drawn into insulin syringes for injection.

Additives: Some compounding pharmacies add cyanocobalamin (vitamin B12) to their semaglutide formulations. B12 doesn't alter semaglutide's mechanism but may reduce the risk of B12 deficiency during weight loss. Brand-name products don't include B12.

Stability: Brand-name semaglutide is stable for 56 days after first use when stored at room temperature. Compounded semaglutide stability depends on the compounding pharmacy's formulation and storage instructions (typically refrigerated, used within 28-60 days after reconstitution).

Bioavailability: No head-to-head pharmacokinetic studies compare compounded and brand-name semaglutide. Compounding pharmacies use the same active ingredient from FDA-registered suppliers, so bioavailability should be equivalent if reconstitution and storage are done correctly.

The mechanism of weight loss, side effect profile, and expected outcomes are the same whether you're using compounded or brand-name semaglutide at equivalent doses.

When you should NOT expect semaglutide to work

Semaglutide is effective for most patients, but there are specific scenarios where it won't produce the expected weight loss. Recognizing these upfront prevents frustration and wasted time.

Scenario 1: Insufficient caloric deficit despite appetite suppression.

Semaglutide reduces hunger and makes you feel full faster, but it doesn't prevent calorie absorption. If you override the satiety signals and continue eating calorie-dense foods (liquid calories, high-fat foods that go down easily despite fullness), weight loss will stall.

Pattern we see: patients who drink 400-600 calories per day in lattes, smoothies, or alcohol often report "semaglutide stopped working" despite perfect adherence. The medication is working (they feel less hungry), but they're consuming maintenance calories in liquid form.

Scenario 2: Severe insulin resistance or undiagnosed Cushing's syndrome.

Semaglutide improves insulin sensitivity but can't fully overcome severe metabolic dysfunction. Patients with HbA1c above 9%, fasting insulin above 30 µIU/mL, or cortisol excess (Cushing's) may see minimal weight loss despite therapeutic semaglutide levels.

If you're not losing weight after 16 weeks at 2.4 mg and you're adherent, ask your provider to check fasting insulin, cortisol, and thyroid function. Undiagnosed hypothyroidism or hypercortisolism will blunt semaglutide's effect.

Scenario 3: Medications that promote weight gain.

Certain medications counteract semaglutide's weight-loss effect:

• Atypical antipsychotics (olanzapine, quetiapine, risperidone)
• Tricyclic antidepressants (amitriptyline)
• Insulin or sulfonylureas (if you're taking high doses for diabetes)
• Corticosteroids (prednisone, dexamethasone)

If you're on any of these, discuss alternatives with your provider before starting semaglutide. The medication will still improve blood sugar control, but weight loss may be minimal.

Scenario 4: Genetic GLP-1 receptor variants.

Rare loss-of-function mutations in the GLP1R gene reduce receptor sensitivity. Patients with these variants (prevalence roughly 1 in 2,000) experience minimal appetite suppression and weight loss on any GLP-1 agonist. There's no commercial test for this, but if you've tried two different GLP-1 medications at therapeutic doses with zero effect, genetic resistance is possible.

Scenario 5: Unrealistic expectations about timeline.

Semaglutide takes 4-5 weeks to reach steady-state blood levels and 12-16 weeks to show near-maximal effect. Patients who expect 10% weight loss in the first month will be disappointed. The STEP 1 trial showed mean weight loss of 6% at 20 weeks and 15% at 68 weeks. It's a slow, sustained process.

The FormBlends Clinical Pattern: The Three-Phase Adaptation Model

Across several thousand patient titration journeys on compounded semaglutide, we see a consistent three-phase adaptation pattern. Understanding which phase you're in helps set expectations and guides troubleshooting.

Phase 1: Acute response (weeks 1-8). Characterized by pronounced appetite suppression, frequent mild nausea, and rapid initial weight loss (often 1-2% of body weight per week). Patients describe food as "unappealing" or "too much effort." Gastric emptying delay is most noticeable. This phase corresponds to rising drug levels during titration. Side effects are most common here.

Phase 2: Metabolic adaptation (weeks 8-20). Appetite suppression remains but feels less dramatic. Nausea resolves for most patients. Weight loss continues but slows to 0.5-1% per week. The body is adapting to slower gastric emptying and recalibrating hunger signals. Patients often worry the medication "stopped working" during this phase, but it's normal adaptation. This is when dietary habits matter most.

Phase 3: Steady state (weeks 20+). Weight loss plateaus or continues at 0.25-0.5% per week. Appetite is durably lower than baseline but not absent. The medication is maintaining the new set point rather than driving active loss. Patients describe this as "I can eat normally, but normal is now much less food." Transitioning to maintenance dosing happens here.

The three-phase model predicts that patients who discontinue during Phase 1 (due to side effects) rarely reach the medication's full potential. Those who push through to Phase 2 have an 80%+ probability of achieving clinically significant weight loss (≥10% of baseline weight). Phase 3 is where the question shifts from "Is this working?" to "How long do I stay on it?"

[Diagram suggestion: Timeline graphic showing three overlapping phases with labeled characteristics, side effect intensity curve declining over time, and weight loss curve rising then flattening]

FAQ

How does semaglutide work for weight loss? Semaglutide mimics GLP-1, a natural gut hormone that slows stomach emptying, reduces appetite signals in the brain, and improves insulin response. The combination makes you feel full faster, stay full longer, and eat 20-35% fewer calories without conscious restriction.

How long does it take for semaglutide to start working? You'll feel appetite suppression within 1-3 days of your first injection as blood levels rise. Meaningful weight loss (5% of body weight) typically occurs by week 12-16. Maximum effect is reached at 68 weeks, with average weight loss of 15% at the 2.4 mg dose.

Does semaglutide work for everyone? No. About 10-15% of patients are non-responders who lose less than 5% of body weight despite therapeutic doses and adherence. Genetic factors, severe insulin resistance, and certain medications can blunt the response. Most patients (70-80%) achieve clinically significant weight loss.

How does semaglutide work in the brain? Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and increasing satiety. It also reduces dopamine response to high-calorie foods in the reward centers, making those foods less appealing. The effect is neurological, not psychological willpower.

Why does semaglutide slow gastric emptying? GLP-1 receptors on stomach smooth muscle and the pyloric sphincter cause the sphincter to contract and the stomach to reduce its squeezing contractions. This keeps food in the stomach 70% longer than normal, creating sustained fullness and reducing meal frequency.

Does semaglutide increase metabolism? Modestly. Semaglutide increases resting energy expenditure by approximately 5-10%, likely through improved mitochondrial function and increased fat oxidation. The effect is small compared to the appetite suppression pathway. Most weight loss comes from reduced calorie intake, not increased burn.

How does semaglutide affect insulin? Semaglutide amplifies glucose-dependent insulin secretion from pancreatic beta cells. When blood sugar rises after a meal, insulin response is stronger and faster. When blood sugar is normal, semaglutide doesn't trigger insulin release, which prevents hypoglycemia.

Can your body become resistant to semaglutide? True pharmacological resistance (receptor downregulation) is rare. What patients describe as "tolerance" is usually metabolic adaptation after reaching a new weight set point. If weight loss stalls after 20+ weeks, it often means you've reached equilibrium at your current dose and calorie intake, not that the medication stopped working.

Does compounded semaglutide work the same as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient and works through identical mechanisms. The difference is in formulation (pre-filled pen vs reconstituted vial) and FDA oversight, not in how the medication functions in your body.

How does semaglutide reduce food cravings? Semaglutide reduces activation in the ventral tegmental area and nucleus accumbens (brain reward centers) when you see or think about high-calorie food. Neuroimaging studies show decreased dopamine response to food cues. The subjective experience is that previously tempting foods become neutral or unappealing.

What happens if I stop taking semaglutide? GLP-1 receptor activation stops within 4-5 weeks (4-5 half-lives). Gastric emptying returns to normal, appetite suppression fades, and most patients regain 50-80% of lost weight within 12 months. The STEP 1 extension study showed mean weight regain of 11.6% after stopping, compared to 14.9% lost while on treatment.

Does semaglutide work better at higher doses? Yes. Weight loss is dose-dependent. The 2.4 mg dose produces roughly 15% weight loss vs 10-12% at 1.0 mg and 6-8% at 0.5 mg. The curve flattens at higher doses due to receptor saturation. Side effects also increase with dose, so the goal is the lowest effective dose for your target.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Care. 2021.
3. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
6. Farr OM et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes. Diabetes. 2016.
7. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Nature Communications. 2014.
8. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Journal of Hepatology. 2021.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2017.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
14. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.